Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16312089 | 1.00 | OPRD1 (0.72) | OPRD1OPRK1OPRM1CYP2D6CHRNA7 | |
| SCHEMBL25681504 | 1.00 | OPRD1 (0.72) | OPRD1OPRK1OPRM1CYP2D6CHRNA7 | |
| SCHEMBL22892792 | 1.00 | OPRD1 (0.72) | OPRD1OPRK1OPRM1CYP2D6CHRNA7 | |
| SCHEMBL12303427 | 1.00 | OPRD1 (0.72) | OPRD1OPRK1OPRM1CYP2D6CHRNA7 | |
| SCHEMBL3844397 | 1.00 | OPRD1 (0.72) | OPRD1OPRK1OPRM1CYP2D6CHRNA7 | |
| SCHEMBL14066449 | 1.00 | OPRD1 (0.72) | OPRD1OPRK1OPRM1CYP2D6CHRNA7 | |
| SCHEMBL11364275 | 0.96 | OPRD1 (0.70) | OPRD1OPRK1OPRM1CYP2D6CHRNA7 | |
| SCHEMBL11364281 | 0.96 | OPRD1 (0.70) | OPRD1OPRK1OPRM1CYP2D6CHRNA7 | |
| SCHEMBL24894803 | 0.90 | OPRD1 (0.61) | OPRD1OPRK1OPRM1CYP2D6CHRNA7 | |
| SCHEMBL1756099 | 0.89 | OPRD1 (0.59) | OPRD1OPRK1OPRM1CYP2D6CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554282-A2 | MORPHINAN DERIVATIVES THE QUATERNARY AMMONIUM SALTS THEREOF SUBSTITUTED IN POSITION 14, METHOD FOR PRODUCTION AND USE THEREOF | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2005-07-20 | — | — | EP | claimed |
| WO-2004005294-A2 | MORPHINAN DERIVATIVES THE QUATERNARY AMMONIUM SALTS THEREOF SUBSTITUTED IN POSITION 14, METHOD FOR PRODUCTION AND USE THEREOF | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2004-01-15 | — | — | WO | claimed |
| EP-2099456-A2 | N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS | Progenics Pharmaceuticals, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080234306-A1 | N-Oxides of 4,5-Epoxy-Morphinanium Analogs | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008070462-A2 | N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-4272541-A | 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them | MILES LABORATORIES, INC. (US) | 1981-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234306-A1 | N-Oxides of 4,5-Epoxy-Morphinanium Analogs | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRK1 3/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.